Incyte names former Novartis president as its chief executive
pharmafile | January 14, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Incyte, Novartis, hoppenot
Biopharma firm Incyte has announced that the former president of Novartis Oncology has been named as its president and chief executive.
Hervé Hoppenot will join the Incyte board of directors and succeeds Dr Paul Friedman in the chief executive role, who is retiring and will continue to serve on the board.
“Hervé’s broad international oncology experience and proven track record in leading successful, high-performing R&D and commercial teams will be of great value as we continue to build upon Incyte’s remarkable success,” said Richard De Schutter, chairman of the Incyte board of directors.
As president of Novartis Oncology Hoppenot was responsible for translational medicine, development, approval and commercialisation, and 8,000 employees in 50 countries.
Prior to his president role Hoppenot served as chief commercial officer and head of Global Product Strategy & Scientific Development. He joined Novartis in 2003 as senior VP, head of Global Marketing and has more than 25 years of experience.
Hoppenot started his career in France with Rhone Poulenc, later known as Aventis, where he served in several senior roles of increasing responsibility, including VP of Oncology and head of its US Oncology business unit.
He said: “The strong science behind Incyte’s R&D programmes and the strength and diversity of the pipeline are compelling and hold much promise for making a difference in the lives of patients. I am honoured to join Incyte.”
Related Content
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …
First malaria medicine for infants under 4.5kg receives approval
Coartem (artemether-lumefantrine) Baby, or Riamet, has been approved by Swissmedic as the first malaria medicine …
